» Journals » Drug Metab Pharmacokinet

Drug Metabolism and Pharmacokinetics

Drug Metabolism and Pharmacokinetics is a peer-reviewed scientific journal that focuses on the study of drug metabolism, pharmacokinetics, and drug-drug interactions. It publishes original research articles, reviews, and case reports, providing valuable insights into the absorption, distribution, metabolism, and excretion of drugs, as well as their effects on the body. The journal serves as a platform for researchers and practitioners to share advancements in understanding drug metabolism and pharmacokinetics, contributing to the development of safe and effective drug therapies.

Details
Abbr. Drug Metab Pharmacokinet
Publisher Elsevier
Start 2002
End Continuing
Frequency Bimonthly
p-ISSN 1347-4367
e-ISSN 1880-0920
Country United Kingdom
Language English
Metrics
h-index / Ranks: 4734 75
SJR / Ranks: 6612 674
CiteScore / Ranks: 6010 4.40
JIF / Ranks: 5004 2.1
Recent Articles
11.
Iwao T, Matsunaga T
Drug Metab Pharmacokinet . 2025 Jan; 60:101045. PMID: 39847977
The intestines are an important organ with a variety of functions. For drug discovery research, experimental animals and Caco-2 cells derived from a human colon carcinoma may be used to...
12.
Sone N, Gotoh S
Drug Metab Pharmacokinet . 2025 Jan; 60:101050. PMID: 39847976
Various attempts have been made to elucidate the mechanisms of human lung development, its physiological functions, and diseases, in the hope of new drug discovery. Recent technological advancements in experimental...
13.
Deguchi S, Yokoi F, Takayama K
Drug Metab Pharmacokinet . 2025 Jan; 60:101041. PMID: 39847975
In the pharmaceutical research of viral respiratory infections, cell culture models have traditionally been used to evaluate the therapeutic effects of candidate compounds. Although cell lines are easy to handle...
14.
Yamazoe Y, Yoshinari K
Drug Metab Pharmacokinet . 2025 Jan; 60:101037. PMID: 39793292
The previously reported Template system for the prediction of human CYP2B6-mediated reactions (Drug Metab Pharmacokinet 26 309-330, 2011) has been refined with the introduction of ideas of allowable width, Trigger-residue...
15.
Nemoto D, Takagaki T, Kitamura A, Tomita Y
Drug Metab Pharmacokinet . 2025 Jan; 60:101043. PMID: 39787632
The second-generation antipsychotic blonanserin is a highly selective, full antagonist of dopamine D and D and serotonin 5-HT receptors. It is currently prescribed for patients with schizophrenia in Japan. We...
16.
Imai S, Kitada A, Ogura A, Akagi M, Hasegawa M, Vasilinin G, et al.
Drug Metab Pharmacokinet . 2024 Dec; 60:101038. PMID: 39729780
CPX-351 (NS-87; Vyxeos®) has a characteristic liposomal formulation and contains cytarabine and daunorubicin at a 5:1 molar ratio, which demonstrates synergistic activity in both in vitro and in vivo animal...
17.
Mizuno S, Gake S, Takabayashi M, Ito Y, Sanada H, Sugimoto N, et al.
Drug Metab Pharmacokinet . 2024 Dec; 60:101035. PMID: 39693856
A retrospective study and an animal study were conducted to investigate factors affecting the transdermal fentanyl dose to achieve adequate pain relief in patients switched from other opioids. In the...
18.
Paolillo V, Jayakumar M, Sheperd C, Tran A, Hoang S, Dao N, et al.
Drug Metab Pharmacokinet . 2024 Dec; 60:101039. PMID: 39667079
Areca nut (AN) is a substance of abuse consumed by millions worldwide, in spite of established oral and systemic toxicities associated with its use. Previous research demonstrates methyl ester alkaloids...
19.
20.
Li K, Gu L, Cai H, Lu H, Mackie K, Guo F
Drug Metab Pharmacokinet . 2024 Nov; 60:101036. PMID: 39567282
Substance use disorders (SUDs) are complex mental health conditions involving a problematic pattern of substance use. Challenges remain in understanding its neural mechanisms, which are likely to lead to improved...